New hope for rare cancers: immunotherapy drug targets tumors regardless of origin

NCT ID NCT06638931

Recruiting now Disease control Sponsor: Instituto do Cancer do Estado de São Paulo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, and researchers will monitor how well the cancer responds.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma adrenal gland cancer adrenal gland neoplasm angiosarcoma anus neoplasm apocrine adenocarcinoma biliary tract neoplasm Biliary Tract Neoplasms bladder urachal adenocarcinoma bladder urachal carcinoma breast secretory carcinoma cancer of unknown primary site Carcinoma, Ovarian Epithelial carcinosarcoma cholangiocarcinoma Endodermal Sinus Tumor endometrial clear cell adenocarcinoma fallopian tube neoplasm fibrolamellar hepatocellular carcinoma fibrosarcoma gallbladder neoplasm granulosa cell tumor hemangioblastoma hepatoblastoma Kaposi's sarcoma leiomyosarcoma mesothelioma metaplastic breast carcinoma MIT family translocation renal cell carcinoma neuroblastoma Neuroectodermal Tumors, Primitive neuroendocrine neoplasm neurofibrosarcoma osteosarcoma ovarian carcinoma parathyroid gland carcinoma Parathyroid Neoplasms penile neoplasm primitive neuroectodermal tumor sarcoma Sertoli-Leydig cell tumor small intestine neoplasm soft tissue sarcoma Thyroid Neoplasms thyroid tumor trophoblastic neoplasm urachus cancer urethra neoplasm Urethral Neoplasms vaginal cancer vaginal neoplasm vulva cancer vulvar neoplasm yolk sac tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOID CYSTIC CARCINOMA ADRENAL GLAND NEOPLASMS ANAL NEOPLASMS ANGIOSARCOMA APOCRINE CARCINOMA BILIARY TRACT NEOPLASMS CANCER OF UNKNOWN PRIMARY CARCINOSARCOMA CHOLANGIOCARCINOMA CLEAR CELL ENDOMETRIAL CANCER FALLOPIAN TUBE NEOPLASMS FIBROLAMELLAR CARCINOMA FIBROSARCOMA GALLBLADDER NEOPLASMS GRANULOSA CELL TUMOR HEMANGIOBLASTOMA HEPATOBLASTOMA KAPOSI SARCOMA LEIOMYOSARCOMA MESOTHELIOMA METAPLASTIC BREAST CARCINOMA NEUROBLASTOMA NEUROENDOCRINE TUMORS NEUROFIBROSARCOMA OSTEOSARCOMA OVARIAN EPITHELIAL CANCER PARATHYROID CARCINOMA PENILE NEOPLASMS PRIMITIVE NEUROECTODERMAL TUMOR SECRETORY CARCINOMA OF BREAST SERTOLI-LEYDIG CELL TUMOR SMALL INTESTINE NEOPLASMS SOFT TISSUE SARCOMA THYROID NEOPLASMS TRANSLOCATION RENAL CELL CARCINOMA TROPHOBLASTIC TUMOR URACHAL CANCER URETHRAL NEOPLASMS VAGINAL NEOPLASMS VULVAR NEOPLASMS YOLK SAC TUMOR

Contacts and locations

Locations

DF Star
NOT_YET_RECRUITING

Brasília, 70390-903, Brazil
Hospital Santa Cruz
NOT_YET_RECRUITING

Curitiba, Paraná, 80420-090, Brazil
Hospital São Carlos
NOT_YET_RECRUITING

Fortaleza, Ceará, 60170-170, Brazil
Hospital São Rafael
NOT_YET_RECRUITING

Salvador, Estado de Bahia, 41253-190, Brazil
IDOR Recife
NOT_YET_RECRUITING

Recife, Pernambuco, 52010-010, Brazil
Instituto D'Or de Pesquisa e Ensino
NOT_YET_RECRUITING

Rio de Janeiro, 22281-100, Brazil
Instituto D'or de Pesquisa e Ensino
RECRUITING

São Paulo, São Paulo, 04.501-000, Brazil
Instituto do Câncer do Estado de São Paulo - ICESP
RECRUITING

São Paulo, São Paulo, 05403-010, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.